CytomX Therapeutics, Inc. (CTMX)
 NASDAQ: CTMX · Real-Time Price · USD
 3.930
 +0.360 (10.08%)
  At close: Nov 3, 2025, 4:00 PM EST
4.080
 +0.150 (3.82%)
  After-hours: Nov 3, 2025, 7:49 PM EST
CytomX Therapeutics Revenue
CytomX Therapeutics had revenue of $18.66M in the quarter ending June 30, 2025, a decrease of -25.71%. This brings the company's revenue in the last twelve months to $141.10M, up 18.01% year-over-year. In the year 2024, CytomX Therapeutics had annual revenue of $138.10M with 36.45% growth.
Revenue (ttm) 
 $141.10M
Revenue Growth 
 +18.01%
P/S Ratio 
 2.70
Revenue / Employee 
 $1,166,116
Employees 
 121
Market Cap 
648.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 138.10M | 36.89M | 36.45% | 
| Dec 31, 2023 | 101.21M | 48.05M | 90.38% | 
| Dec 31, 2022 | 53.16M | 15.85M | 42.48% | 
| Dec 31, 2021 | 37.31M | -31.12M | -45.47% | 
| Dec 31, 2020 | 68.43M | 41.53M | 154.36% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| AbbVie | 59.64B | 
| Eli Lilly and Company | 59.42B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
CTMX News
- 4 days ago - CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
 - 14 days ago - CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer - GlobeNewsWire
 - 21 days ago - CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible - Seeking Alpha
 - 22 days ago - Renewed Tariff Fears Spotlight Top Performing Stocks Since April - Seeking Alpha
 - 4 weeks ago - CytomX: A Fresh Start With New Drugs After Total Pipeline Failure - Seeking Alpha
 - 7 weeks ago - CytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
 - 2 months ago - CytomX Therapeutics to Present at Upcoming September Investor Conferences - GlobeNewsWire
 - 2 months ago - CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study - GlobeNewsWire